In the US, the Orange Book is a publication from the US FDA that
identifies drug products with marketing approval from the FDA and
related patent and exclusivity information. Information in the
Orange Book could be used in actions under the Hatch-Waxman Act,
which allows a patentee to file an artificial act of infringement
that allows the drug innovator to file suit before the generic drug
is commercialized, such that the drug marketing approval process of
the generic drug at the US FDA could be suspended.
China is required to introduce a similar system under the
Phase-I Trade Agreements signed with the US in January 2020. I have
been following this since then, and have several articles and posts
on this topic. Recently, this "CN Orange Book" (official
name: China listed drugs patent information registration platform)
has become officially online on 29 June 2021, with many
developments thereafter, and I have received many questions on how
to use this. This motivates